TY - JOUR
T1 - Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study
AU - On behalf of the Dutch Upper GI Cancer Group (DUCG)
AU - van Kleef, J. J.
AU - Dijksterhuis, W. P. M.
AU - van den Boorn, H. G.
AU - Prins, M.
AU - Verhoeven, R. H. A.
AU - Gisbertz, S. S.
AU - Slingerland, M.
AU - Mohammad, N. Haj
AU - Creemers, G. J.
AU - Neelis, K. J.
AU - Heisterkamp, J.
AU - Rosman, C.
AU - Ruurda, J. P.
AU - Kouwenhoven, E. A.
AU - van de Poll-Franse, L. V.
AU - van Oijen, M. G. H.
AU - Sprangers, M. A. G.
AU - van Laarhoven, H. W. M.
N1 - Funding Information: RHAV reports grants from BMS and Roche. NHM reports a consult/advisory role for BMS, MSD Servier, Eli Lilly, Astra Zeneca, research grant from Servier. MGHvO reports grants from Amgen, BMS, Lilly, Nordic, Merck, Roche, and Servier. HWMvL reports a consult/advisory role for BMS, Celgene, Lilly, Merck, Nordic, and Servier and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche and Servier. The other authors declare that they have no conflicts of interest. Funding Information: This project is supported by a grant of the Dutch Cancer Society (KWF), grant number UVA 2014-7000. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry, and the POCOP team for collecting the questionnaires. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer. Methods: Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS. Results: In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82–0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59–0.94), followed by fatigue, pain, insomnia and role functioning. Conclusion: In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models.
AB - Background: Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer. Methods: Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS. Results: In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82–0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59–0.94), followed by fatigue, pain, insomnia and role functioning. Conclusion: In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models.
KW - Gastric cancer
KW - Oesophageal cancer
KW - Population based
KW - Prognostic
KW - Quality of life
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85110665803&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10120-021-01209-1
DO - https://doi.org/10.1007/s10120-021-01209-1
M3 - Article
C2 - 34251543
SN - 1436-3291
VL - 24
SP - 1203
EP - 1212
JO - Gastric cancer
JF - Gastric cancer
IS - 6
ER -